Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
TrueBinding, Inc. currently has 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters involve 4 distinct examiners and are distributed across 2 distinct art units. This arrangement shows that while the company's work is concentrated in 2 specific technical divisions, it is being reviewed by a relatively large group of individual examiners. This can lead to varied perspectives on the patentability of the company's biotechnological claims.
BELYAVSKYI, MICHAIL A is the busiest examiner for the portfolio. This examiner is handling 1 pending office action, while the company manages a total of 4 pending actions across its various filings. With 4 distinct examiners involved, the company must be prepared for different sets of examiner preferences and interpretations. Although the work is limited to 2 distinct art units, the high number of examiners relative to the number of pending actions suggests a lack of consolidation. Practitioners must carefully track the active filings to ensure that arguments made to 1 examiner do not conflict with those made to the others in the same technology area.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (25%) |
| Double-patenting only | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BELYAVSKYI, MICHAIL A | 1 | 64.2% | +27.6% |
| HAMA, JOANNE | 1 | 25.7% | +40.0% |
| WANG, CHANG YU | 1 | 33.5% | +53.5% |
| ALLEN, MARIANNE P | 1 | 60.1% | +18.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18637068 | METHODS OF TREATING EYE DISEASE | BELYAVSKYI, MICHAIL A | — |
| 18492607 | ANTI-GAL3 ANTIBODY FORMULATIONS AND METHODS OF USE THEREOF | HAMA, JOANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18053191 | METHODS OF TREATING OR INHIBITING CARDIOVASCULAR DISEASES | WANG, CHANG YU | 26d overdue |
| 18637068 | METHODS OF TREATING EYE DISEASE | BELYAVSKYI, MICHAIL A | — |
| 18492607 | ANTI-GAL3 ANTIBODY FORMULATIONS AND METHODS OF USE THEREOF | HAMA, JOANNE | — |
| 17834703 | ANTI-GAL3 ANTIBODIES AND METHODS OF USE FOR INSULIN RESISTANCE | ALLEN, MARIANNE P | — |
| Art Unit | Apps |
|---|---|
| 1647 | 2 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18637068 | METHODS OF TREATING EYE DISEASE | BELYAVSKYI, MICHAIL A | — | §103§112Other | Non-Final OA | — | Pending | Apr 16, 2024 |
| 18492607 | ANTI-GAL3 ANTIBODY FORMULATIONS AND METHODS OF USE THEREOF | HAMA, JOANNE | 1647 | §103§112Other | Non-Final OA | — | Pending | Oct 23, 2023 |
| 18053191 | METHODS OF TREATING OR INHIBITING CARDIOVASCULAR DISEASES | WANG, CHANG YU | 1675 | §112 | Final Rejection | 26d overdue | Pending | Nov 07, 2022 |
| 17834703 | ANTI-GAL3 ANTIBODIES AND METHODS OF USE FOR INSULIN RESISTANCE | ALLEN, MARIANNE P | 1647 | DP | Non-Final OA | — | Pending | Jun 07, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial